
## Cyrus Chargari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7237989/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Local treatment of rhabdomyosarcoma of the female genital tract: Expert consensus from the Children's Oncology Group, the European Softâ€issue Sarcoma Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatric Blood and Cancer, 2023, 70, e28601.	1.5	18
2	Impact of Vaginal Symptoms and Hormonal Replacement Therapy on Sexual Outcomes After Definitive Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: Results from the EMBRACE-I Study. International Journal of Radiation Oncology Biology Physics, 2022, 112, 400-413.	0.8	20
3	Clear Cell Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Management. Annals of Surgical Oncology, 2022, 29, 1165-1170.	1.5	5
4	Severity and Persistency of Late Gastrointestinal Morbidity in Locally Advanced Cervical Cancer: Lessons Learned From EMBRACE-I and Implications for the Future. International Journal of Radiation Oncology Biology Physics, 2022, 112, 681-693.	0.8	14
5	Risk Factors for Late Persistent Fatigue After Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: An Analysis From the EMBRACE-I Study. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1177-1189.	0.8	6
6	Inoperable scalp cutaneous angiosarcoma: Complete response after definitive external beam radiation therapy – brachytherapy association. Oral Oncology, 2022, 125, 105715.	1.5	1
7	Brachytherapy for the Conservative Treatment of Female Peri-Urethral Carcinoma. Cancers, 2022, 14, 845.	3.7	0
8	Role of Brachytherapy in the Postoperative Management of Endometrial Cancer: Decision-Making Analysis among Experienced European Radiation Oncologists. Cancers, 2022, 14, 906.	3.7	4
9	Combined modality including novel sensitizers in gynecological cancers. International Journal of Gynecological Cancer, 2022, 32, 389-401.	2.5	2
10	Brachytherapy for Pediatric Patients at Gustave Roussy Cancer Campus: A Model of International Cooperation for Highly Specialized Treatments. International Journal of Radiation Oncology Biology Physics, 2022, 113, 602-613.	0.8	11
11	Neoadjuvant chemotherapy in fertility-sparing management of FIGO 2018 stage IB2 cervical cancer. International Journal of Gynecological Cancer, 2022, 32, 680-685.	2.5	0
12	Current Standards in the Management of Early and Locally Advanced Cervical Cancer: Update on the Benefit of Neoadjuvant/Adjuvant Strategies. Cancers, 2022, 14, 2449.	3.7	10
13	Endometrioid Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Managements. Annals of Surgical Oncology, 2022, , .	1.5	0
14	Providing Patients with Locally Advanced Cervical Cancer Access to Brachytherapy: Experience from a Referral Network for Women Treated in Overseas France. Cancers, 2022, 14, 2935.	3.7	1
15	The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) consensus statements on pre-invasive vulvar lesions. International Journal of Gynecological Cancer, 2022, 32, 830-845.	2.5	17
16	Two New Potential Therapeutic Approaches in Radiation Cystitis Derived from Mesenchymal Stem Cells: Extracellular Vesicles and Conditioned Medium. Biology, 2022, 11, 980.	2.8	5
17	Implementation of Image-Guided Brachytherapy for Pediatric Vaginal Cancers: Feasibility and Early Clinical Results. Cancers, 2022, 14, 3247.	3.7	4
18	Results After Conservative Surgery of Stage II/III Serous Borderline Ovarian Tumors. Annals of Surgical Oncology, 2021, 28, 3597-3604.	1.5	11

#	Article	IF	CITATIONS
19	Dose-Volume Effects and Risk Factors for Late Diarrhea in Cervix Cancer Patients After Radiochemotherapy With Image Guided Adaptive Brachytherapy in the EMBRACE I Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 688-700.	0.8	31
20	EANM/SNMMI practice guideline for [18F]FDG PET/CT external beam radiotherapy treatment planning in uterine cervical cancer v1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1188-1199.	6.4	23
21	Analysis of Radiation Dose/Volume Effect Relationship for Anorectal Morbidity in Children Treated for Pelvic Malignancies. International Journal of Radiation Oncology Biology Physics, 2021, 109, 231-241.	0.8	7
22	Drug–Radiotherapy Combination Trial Developments—Response. Clinical Cancer Research, 2021, 27, 356-356.	7.0	0
23	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiotherapy and Oncology, 2021, 154, 327-353.	0.6	96
24	Pulse-dose-rate interstitial brachytherapy in anal squamous cell carcinoma: clinical outcomes and patients' health quality perception. Journal of Contemporary Brachytherapy, 2021, 13, 263-272.	0.9	3
25	Venezia applicator with oblique needles improves clinical target volume coverage in distal parametrial tumor residue compared to parallel needles only. Journal of Contemporary Brachytherapy, 2021, 13, 24-31.	0.9	9
26	Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of CSF-GETO and SFCE, with the support of the NETSARC+ network. Bulletin Du Cancer, 2021, 108, 163-176.	1.6	7
27	ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 153-190.	2.8	99
28	Image-Guided Adaptive Brachytherapy (IGABT) for Primary Vaginal Cancer: Results of the International Multicenter RetroEMBRAVE Cohort Study. Cancers, 2021, 13, 1459.	3.7	9
29	Pulsed Dose Rate Brachytherapy of Lip Carcinoma: Clinical Outcome and Quality of Life Analysis. Cancers, 2021, 13, 1387.	3.7	2
30	Image-Guided Brachytherapy for Salvage Reirradiation: A Systematic Review. Cancers, 2021, 13, 1226.	3.7	13
31	Brenner Borderline Ovarian Tumor: A Case Series and Literature Review. Annals of Surgical Oncology, 2021, 28, 6714-6720.	1.5	9
32	MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncology, The, 2021, 22, 538-547.	10.7	268
33	Glassy cell carcinoma of the uterine cervix: 20-year experience from a comprehensive cancer center. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2021, 25, 207-212.	1.4	3
34	COVID-19-Associated Pneumonia: Radiobiological Insights. Frontiers in Pharmacology, 2021, 12, 640040.	3.5	4
35	ASO Visual Abstract: Brenner Borderline Ovarian Tumor—A Case Series and Literature Review. Annals of Surgical Oncology, 2021, 28, 468-469.	1.5	1

Metabolic features of cancer cells impact immunosurveillance. , 2021, 9, e002362.

#	Article	IF	CITATIONS
37	Systematic Screening of COVID-19 Disease Based on Chest CT and RT-PCR for Cancer Patients Undergoing Radiation Therapy in a Coronavirus French Hotspot. International Journal of Radiation Oncology Biology Physics, 2021, 110, 947-956.	0.8	9
38	PAX3â€NCOA1 alveolar rhabdomyosarcoma of the tongue: A rare entity with challenging diagnosis and management. Pediatric Blood and Cancer, 2021, 68, e29288.	1.5	2
39	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer, 2021, 31, 12-39.	2.5	859
40	Chronic Inflammation and Radiation-Induced Cystitis: Molecular Background and Therapeutic Perspectives. Cells, 2021, 10, 21.	4.1	24
41	Cervical Cancer and Fertility-Sparing Treatment. Journal of Clinical Medicine, 2021, 10, 4825.	2.4	9
42	Second malignancy (SM) in prostate cancer patients treated with SBRT and other contemporary radiation techniques. Radiotherapy and Oncology, 2021, 164, 251-252.	0.6	1
43	ASO Visual Abstract: Clear CellÂBorderlineÂOvarianÂTumor: ClinicalÂCharacteristics, Prognosis, and Management. Annals of Surgical Oncology, 2021, , 1.	1.5	1
44	Radiobiology: Foundation and New Insights in Modeling Brachytherapy Effects. Seminars in Radiation Oncology, 2020, 30, 4-15.	2.2	10
45	Image-Guided Gynecologic Brachytherapy for Cervical Cancer. Seminars in Radiation Oncology, 2020, 30, 16-28.	2.2	14
46	Recommendations from gynaecological (GYN) GEC-ESTRO working group – ACROP: Target concept for image guided adaptive brachytherapy in primary vaginal cancer. Radiotherapy and Oncology, 2020, 145, 36-44.	0.6	32
47	A new score based on biomarker values to predict the prognosis of locally advanced cervical cancer. Gynecologic Oncology, 2020, 159, 534-538.	1.4	5
48	Incorporating Magnetic Resonance Imaging (MRI) Based Radiation Therapy Response Prediction into Clinical Practice for Locally Advanced Cervical Cancer Patients. Seminars in Radiation Oncology, 2020, 30, 291-299.	2.2	7
49	PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. International Journal of Gynecological Cancer, 2020, 30, 2002-2007.	2.5	135
50	Brachytherapy Issues and Priorities in the Context of the Coronavirus Disease 2019 (COVID-19) Outbreak. Advances in Radiation Oncology, 2020, 5, 640-643.	1.2	9
51	Implementation of image-guided brachytherapy as part of non-surgical treatment in inoperable endometrial cancer patients. Gynecologic Oncology, 2020, 158, 323-330.	1.4	14
52	Evaluation of adjuvant vaginal vault brachytherapy in early stage cervical cancer patients. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 860-865.	1.4	5
53	Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research. Clinical Cancer Research, 2020, 26, 4723-4736.	7.0	23
54	Analysis of Systemic Inflammatory Factors and Survival Outcomes in Endometrial Cancer Patients Staged I-III FIGO and Treated with Postoperative External Radiotherapy. Journal of Clinical Medicine, 2020, 9, 1441.	2.4	14

#	Article	IF	CITATIONS
55	Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. European Journal of Cancer, 2020, 135, 103-112.	2.8	11
56	Interaction between the Number of Chemotherapy Cycles and Brachytherapy Dose/Volume Parameters in Locally Advanced Cervical Cancer Patients. Journal of Clinical Medicine, 2020, 9, 1653.	2.4	10
57	Hypnosedation for endocavitary uterovaginal applications: A pilot study. Brachytherapy, 2020, 19, 462-469.	0.5	5
58	Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors. Gynecologic Oncology, 2020, 158, 659-665.	1.4	2
59	Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer. Lancet Oncology, The, 2020, 21, e157-e167.	10.7	39
60	Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1141-1152.	0.8	17
61	Brachytherapy: An overview for clinicians. Ca-A Cancer Journal for Clinicians, 2019, 69, 386-401.	329.8	150
62	Total Reference Air Kerma is Associated with Late Bowel Morbidity in Locally Advanced Cervical Cancer Patients Treated with Image-Guided Adaptive Brachytherapy. Journal of Clinical Medicine, 2019, 8, 125.	2.4	17
63	Should We Cease to Perform Salvage Hysterectomy After Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer?. Anticancer Research, 2019, 39, 2919-2926.	1.1	14
64	Recommendations for the organisation of care in paediatric radiation oncology across Europe: a SIOPE–ESTRO–PROS–CCI-Europe collaborative project in the framework of the JARC. European Journal of Cancer, 2019, 114, 47-54.	2.8	19
65	Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy. OncoImmunology, 2019, 8, e1574197.	4.6	16
66	Radiobiological optimization comparison between pulse-dose-rate and high-dose-rate brachytherapy in patients with locally advanced cervical cancer. Brachytherapy, 2019, 18, 370-377.	0.5	7
67	Risk Factors for Ureteral Stricture After Radiochemotherapy Including Image Guided Adaptive Brachytherapy in Cervical Cancer: Results From the EMBRACE Studies. International Journal of Radiation Oncology Biology Physics, 2019, 103, 887-894.	0.8	39
68	Risk of Late Urinary Complications Following Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: Refining Bladder Dose-Volume Parameters. International Journal of Radiation Oncology Biology Physics, 2018, 101, 411-420.	0.8	34
69	Image-guided adaptive brachytherapy in primary vaginal cancers: AÂmonocentric experience. Brachytherapy, 2018, 17, 571-579.	0.5	20
70	Dose-volume effects in pathologic lymph nodes in locally advanced cervical cancer. Gynecologic Oncology, 2018, 148, 461-467.	1.4	33
71	Bloc pénien pour curiethérapie de verge chez l'adulte. Anesthésie & Réanimation, 2018, 4, 496-498.	0.1	Ο
72	Multimodal Management of Locally Advanced Neuroendocrine Cervical Carcinoma: A Single Institution Experience. International Journal of Gynecological Cancer, 2018, 28, 1013-1019.	2.5	6

#	Article	IF	CITATIONS
73	Long-term evaluation of urinary, sexual, and quality of life outcomes after brachytherapy for penile carcinoma. Brachytherapy, 2018, 17, 221-226.	0.5	13
74	A score combining baseline neutrophilia and primary tumor SUVpeak measured from FDG PET is associated with outcome in locally advanced cervical cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 187-195.	6.4	25
75	Brachytherapy for conservative treatment of invasive penile carcinoma in older patients: Single institution experience. Journal of Geriatric Oncology, 2018, 9, 275-278.	1.0	5
76	Tumor Shrinkage During Chemoradiation in Locally Advanced Cervical Cancer Patients: Prognostic Significance, and Impact for Image-Guided Adaptive Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 362-372.	0.8	48
77	Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. Radiotherapy and Oncology, 2018, 127, 423-430.	0.6	54
78	Pharmacological modulation of radiation-induced oral mucosal complications. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2018, 22, 429-437.	1.4	18
79	Radiomics in Nuclear Medicine Applied to Radiation Therapy: Methods, Pitfalls, and Challenges. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1117-1142.	0.8	86
80	Multivariate normal tissue complication probability modeling of vaginal late toxicity after brack brack brackytherapy for cervical cancer. Brachytherapy, 2018, 17, 922-928.	0.5	6
81	Leukocytosis, prognosis biomarker in locally advanced head and neck cancer patients after chemoradiotherapy. Clinical and Translational Radiation Oncology, 2018, 12, 8-15.	1.7	11
82	Second cancers after radiotherapy: update and recommandations. Radioprotection, 2018, 53, 101-105.	1.0	15
83	New insights in radiation-induced leukoencephalopathy: a prospective cross-sectional study. Supportive Care in Cancer, 2018, 26, 4217-4226.	2.2	26
84	Testicular transposition in children undergoing brachytherapy for bladder and/or prostate rhabdomyosarcoma. Journal of Pediatric Surgery, 2018, 53, 1428-1431.	1.6	13
85	Radiobiology of brachytherapy: The historical view based on linear quadratic model and perspectives for optimization. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2018, 22, 312-318.	1.4	18
86	3D brachytherapy for cervical cancer: New optimization ways. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2018, 22, 345-351.	1.4	4
87	Locally advanced cervical cancer with bladder invasion: clinical outcomes and predictive factors for vesicovaginal fistulae. Oncotarget, 2018, 9, 9299-9310.	1.8	21
88	Transitory Stoma at the Time of Complete Cytoreductive Surgery Affects Survival for Patients with Advanced-stage Ovarian Cancer. Anticancer Research, 2018, 38, 1517-1523.	1.1	5
89	Outcome of early stage cervical cancer patients treated according to a radiosurgical approach: Clinical results and prognostic factors. Gynecologic Oncology, 2017, 144, 541-546.	1.4	22
90	Brachytherapy as part of the conservative treatment for primary and recurrent vulvar carcinoma. Brachytherapy, 2017, 16, 518-525.	0.5	15

#	Article	IF	CITATIONS
91	Brachytherapy for Conservative Treatment of Invasive Penile Carcinoma: Prognostic Factors and Long-Term Analysis of Outcome. International Journal of Radiation Oncology Biology Physics, 2017, 99, 563-570.	0.8	39
92	Contribution of image-guided adaptive brachytherapy to pelvic nodes treatment in locally advanced cervical cancer. Brachytherapy, 2017, 16, 366-372.	0.5	20
93	Brachytherapy Combined With Surgery for Conservative Treatment of Children With Bladder Neck and/or Prostate Rhabdomyosarcoma. International Journal of Radiation Oncology Biology Physics, 2017, 98, 352-359.	0.8	47
94	Optimizing Local Control in Highâ€Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment. Oncologist, 2017, 22, 182-188.	3.7	6
95	The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy. Molecular Cancer Therapeutics, 2017, 16, 2107-2119.	4.1	23
96	Assessment of the novel online delineation workshop dummy run approach using FALCON within a European multicentre trial in cervical cancer (RAIDs). Radiotherapy and Oncology, 2017, 124, 130-138.	0.6	7
97	In Regard to Swanick etÂal. International Journal of Radiation Oncology Biology Physics, 2017, 97, 638.	0.8	1
98	Pelvic radiotherapy in the setting of rheumatoid arthritis: Refining the paradigm. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2017, 21, 109-113.	1.4	3
99	Leukocytosis and neutrophilia predicts outcome in anal cancer. Radiotherapy and Oncology, 2017, 122, 137-145.	0.6	50
100	Melanoma: Last call for radiotherapy. Critical Reviews in Oncology/Hematology, 2017, 110, 13-19.	4.4	39
101	Neutrophils, a candidate biomarker and target for radiation therapy?. Acta Oncológica, 2017, 56, 1522-1530.	1.8	50
102	Navigating the highlights of phase III trials: a watchful eye on evidence-based radiotherapy. Annals of Oncology, 2017, 28, 2691-2697.	1.2	7
103	Clinical outcomes after interstitial brachytherapy for early-stage nasal squamous cell carcinoma. Brachytherapy, 2017, 16, 1021-1027.	0.5	11
104	Pulsed-dose rate brachytherapy for pediatric bladder prostate rhabdomyosarcoma: Compliance and early clinical results. Radiotherapy and Oncology, 2017, 124, 285-290.	0.6	20
105	Brain metastases from non-small cell lung carcinoma: Changing concepts for improving patients' outcome. Critical Reviews in Oncology/Hematology, 2017, 116, 32-37.	4.4	7
106	External validation of leukocytosis and neutrophilia as a prognostic marker in anal carcinoma treated with definitive chemoradiation. Radiotherapy and Oncology, 2017, 124, 110-117.	0.6	26
107	Diffusion-weighted MRI in image-guided adaptive brachytherapy: Tumor delineation feasibility study and comparison with GEC-ESTRO guidelines. Brachytherapy, 2017, 16, 956-963.	0.5	13
108	Concerns about cardiotoxicity in the HERA trial. Lancet, The, 2017, 390, 2767.	13.7	0

#	Article	IF	CITATIONS
109	Radiotherapy among nonagenarians with anal or rectal carcinoma: should we avoid or adapt treatment?. Chinese Journal of Cancer, 2017, 36, 56.	4.9	3
110	Radiation induced gastroparesis—case report and literature review. Journal of Gastrointestinal Oncology, 2017, 8, E52-E55.	1.4	5
111	Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy. Journal of Gastrointestinal Oncology, 2017, 8, 173-179.	1.4	14
112	Locally advanced cervical cancer: Is it relevant to report image-guided adaptive brachytherapy using point A dose?. Brachytherapy, 2017, 16, 862-869.	0.5	7
113	Leukocytosis and neutrophilia predict outcome in locally advanced esophageal cancer treated with definitive chemoradiation. Oncotarget, 2017, 8, 11579-11588.	1.8	36
114	Prediction of cervical cancer recurrence using textural features extracted from 18F-FDG PET images acquired with different scanners. Oncotarget, 2017, 8, 43169-43179.	1.8	100
115	Flattening Filter Free vs. Flattened Beams for Lung Stereotactic Body Radiation Therapy. Anticancer Research, 2017, 37, 5133-5139.	1.1	5
116	Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients. Oncotarget, 2016, 7, 25549-25557.	1.8	15
117	Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma. Anti-Cancer Drugs, 2016, 27, 427-432.	1.4	17
118	Clinical Impact of Bevacizumab in Patients with Relapsed Clioblastoma: Focus on a Real-Life Monocentric SurVey (SV1 Study). Chemotherapy, 2016, 61, 269-274.	1.6	1
119	Can immunostimulatory agents enhance the abscopal effect of radiotherapy?. European Journal of Cancer, 2016, 62, 36-45.	2.8	105
120	Quality of life and functional outcome of male patients with bladder–prostate rhabdomyosarcoma treated with conservative surgery and brachytherapy during childhood. Brachytherapy, 2016, 15, 306-311. d brachytherapy in locally advanced central cancer. Small bowels mulmath	0.5	30
121	xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si1.gif" overflow="scroll"> <mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>0.1</mml:mn><mml:r xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si2.gif" overflow="scroll"&gt;<mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:ms.< td=""><td>nsup&gt;<mi 0.5</mi </td><td>nl:mrow&gt; <n 11</n </td></mml:ms.<></mml:mrow></mml:msub></mml:mrow></mml:r </mml:mrow></mml:msub></mml:mrow>	nsup> <mi 0.5</mi 	nl:mrow> <n 11</n 
122	Brachytherapy, 2016, 15, 463-470. Image-guided adaptive brachytherapy in cervical cancer: Patterns of relapse by brachytherapy planning parameters. Brachytherapy, 2016, 15, 456-462.	0.5	12
123	Immunotherapy in head and neck cancer: Harnessing profit on a system disruption. Oral Oncology, 2016, 62, 153-162.	1.5	8
124	Post radiation hysterectomy in locally advanced cervical cancer: Outcomes and dosimetric impact. Radiotherapy and Oncology, 2016, 120, 460-466.	0.6	22
125	Tumor dose–volume response in image-guided adaptive brachytherapy for cervical cancer: A meta-regression analysis. Brachytherapy, 2016, 15, 537-542.	0.5	30
126	Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature. Fertility and Sterility, 2016, 106, 1195-1211.e5.	1.0	160

#	Article	IF	CITATIONS
127	Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy. Clinical and Experimental Metastasis, 2016, 33, 775-785.	3.3	6
128	CTV to PTV in cervical cancer: From static margins to adaptive radiotherapy. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2016, 20, 622-628.	1.4	11
129	Preoperative image-guided brachytherapy in early stage cervical cancers. Radiotherapy and Oncology, 2016, 120, 455-459.	0.6	14
130	Image-guided adaptive brachytherapy in locally advanced cervical cancer: recent advances and perspectives. Current Opinion in Oncology, 2016, 28, 419-428.	2.4	17
131	Brachytherapy and fertility. Human Fertility, 2016, 19, 85-89.	1.7	2
132	Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. Lancet Oncology, The, 2016, 17, e240-e253.	10.7	206
133	Conflict of interests for radiation oncologists: Harnessing disclosures from policy to reality. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2016, 20, 176-180.	1.4	4
134	Radiotherapy for gynecologic cancer in nonagenarian patients: a framework for new paradigms. Chinese Journal of Cancer, 2016, 35, 43.	4.9	5
135	Vaginal dose assessment in image-guided brachytherapy for cervical cancer: Can we really rely on dose-point evaluation?. Brachytherapy, 2016, 15, 169-176.	0.5	8
136	Risk of second cancers in the era of modern radiation therapy: does the risk/benefit analysis overcome theoretical models?. Cancer and Metastasis Reviews, 2016, 35, 277-288.	5.9	35
137	Nanoparticles in radiation oncology: From bench-side to bedside. Cancer Letters, 2016, 375, 256-262.	7.2	76
138	Intensity-modulated salvage radiotherapy with simultaneous integrated boost for local recurrence of prostate carcinoma: a pilot study on the place of PET-choline for guiding target volume delineation. British Journal of Radiology, 2016, 89, 20150579.	2.2	7
139	Optimize and refine therapeutic index in radiation therapy: Overview of a century. Cancer Treatment Reviews, 2016, 45, 58-67.	7.7	60
140	Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 1088-1098.	0.8	77
141	Dosimetric study of volumetric arc modulation with RapidArc and intensity-modulated radiotherapy in patients with cervical cancer and comparison with 3-dimensional conformal technique for definitive radiotherapy in patients with cervical cancer. Medical Dosimetry, 2016, 41, 9-14.	0.9	27
142	Chemotherapy Regimen in Nonagenarian Cancer Patients: A Bi-Institutional Experience. Chemotherapy, 2016, 61, 65-71.	1.6	9
143	Neutrophilia in locally advanced cervical cancer: A novel biomarker for image-guided adaptive brachytherapy?. Oncotarget, 2016, 7, 74886-74894.	1.8	36
144	Hypofractionated radiation therapy for treatment of bladder carcinoma in patients aged 90Âyears and more: A new paradigm to be explored?. International Urology and Nephrology, 2015, 47, 1129-1134.	1.4	10

#	Article	IF	CITATIONS
145	Thromboembolic events following brachytherapy:. Journal of Contemporary Brachytherapy, 2015, 1, 76-78.	0.9	9
146	D2cm3/DICRU ratio as a surrogate of bladder hotspots localizations during image-guided adaptive brachytherapy for cervical cancer: Assessment and implications in late urinary morbidity analysis. Brachytherapy, 2015, 14, 300-307.	0.5	17
147	Cellular and molecular portrait of eleven human glioblastoma cell lines under photon and carbon ion irradiation. Cancer Letters, 2015, 360, 10-16.	7.2	18
148	Impact of treatment time and dose escalation on local control in locally advanced cervical cancer treated by chemoradiation and image-guided pulsed-dose rate adaptive brachytherapy. Radiotherapy and Oncology, 2015, 114, 257-263.	0.6	129
149	Safety of spinal radiotherapy in metastatic cancer patients receiving bevacizumab therapy. Anti-Cancer Drugs, 2015, 26, 443-447.	1.4	2
150	What to expect from immediate salvage hysterectomy following concomitant chemoradiation and image-guided adaptive brachytherapy in locally advanced cervical cancer. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2015, 19, 710-717.	1.4	14
151	Pulsed-dose rate image-guided adaptive brachytherapy in cervical cancer: Dose–volume effect relationships for the rectum and bladder. Radiotherapy and Oncology, 2015, 116, 226-232.	0.6	50
152	Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer. Gynecologic Oncology, 2015, 139, 288-294.	1.4	91
153	Correlation of Physical Activities and Breast Cancer Characteristics: A Prospective Analysis with Special Focus on Triple Negative Breast Cancer. Oncology, 2015, 89, 262-268.	1.9	3
154	Interstitial pulsed-dose-rate brachytherapy for the treatment of squamous cell anal carcinoma: A retrospective single institution analysis. Brachytherapy, 2015, 14, 549-553.	0.5	7
155	Radiotherapy for head and neck cancer in nonagenarian patients: a possible cornerstone?. European Archives of Oto-Rhino-Laryngology, 2015, 272, 719-725.	1.6	8
156	Epstein-Barr virus reactivation in critically ill immunocompetent patients. Biomedical Journal, 2015, 38, 70.	3.1	55
157	Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use. Journal of Chemotherapy, 2014, 26, 253-255.	1.5	3
158	Focal or combined modality for the management of brain metastasis: did high tech radiotherapy superseded drug-radiotherapy combination?. Annals of Oncology, 2014, 25, 2293-2294.	1.2	2
159	Preventing radiotherapy-induced side effects on deep brain stimulators: the need for a multidisciplinary management. British Journal of Neurosurgery, 2014, 28, 107-109.	0.8	5
160	Individualizing Adjuvant Radiotherapy in Patients With Breast Cancer: Let's Not Get Ahead of Ourselves. Journal of Clinical Oncology, 2014, 32, 3339-3340.	1.6	1
161	Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death and Differentiation, 2014, 21, 92-99.	11.2	181
162	Portrait, treatment choices and management of breast cancer in nonagenarians: An ongoing challenge. Breast, 2014, 23, 221-225.	2.2	5

#	Article	IF	CITATIONS
163	Feasibility of radiation therapy in patients 90years of age and older: A French multicentre analysis. European Journal of Cancer, 2014, 50, 1490-1497.	2.8	23
164	Successful readministration of trastuzumab after severe immune reactions in two breast cancer patients. Investigational New Drugs, 2014, 32, 573-574.	2.6	5
165	Epithelioid hemangioendothelioma of the spine treated with RapidArc volumetric-modulated radiotherapy. Medical Dosimetry, 2014, 39, 242-245.	0.9	7
166	Comparison between the ICRU rectal point and modern volumetric parameters in brachytherapy for locally advanced cervical cancer. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2014, 18, 177-182.	1.4	12
167	Cardiotoxicity Research in Breast Cancer Patients: Past and Future. American Journal of Cardiology, 2014, 113, 1447-1448.	1.6	11
168	General management of nonagenarian patients: a review of the literature. Swiss Medical Weekly, 2014, 144, w14059.	1.6	14
169	Radiation therapy and immunotherapy: Implications for a combined cancer treatment. Critical Reviews in Oncology/Hematology, 2013, 85, 278-287.	4.4	61
170	Complications of thoracic radiotherapy. Presse Medicale, 2013, 42, e342-e351.	1.9	45
171	Combination of vascular disrupting agents and ionizing radiation. Critical Reviews in Oncology/Hematology, 2013, 86, 143-160.	4.4	39
172	Complications of chemotherapy, a basic science update. Presse Medicale, 2013, 42, e352-e361.	1.9	30
173	Analysis of Feasibility and Toxicity of Radiotherapy in Centenarians. Journal of the American Geriatrics Society, 2013, 61, 1833-1835.	2.6	4
174	Understanding the functions of tumor stroma in resistance to ionizing radiation: Emerging targets for pharmacological modulation. Drug Resistance Updates, 2013, 16, 10-21.	14.4	36
175	Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review. Cancer and Metastasis Reviews, 2013, 32, 479-492.	5.9	46
176	First assessment of whole-brain radiation therapy combined with pemetrexed-based chemotherapy in non-small-cell lung carcinoma. Anti-Cancer Drugs, 2013, 24, 736-742.	1.4	7
177	IGF-1R Targeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model: An Opportunity to Increase the Efficacy of Standard Therapy. Molecular Cancer Therapeutics, 2013, 12, 1213-1222.	4.1	40
178	Controversies and challenges regarding the impact of radiation therapy on survival. Annals of Oncology, 2013, 24, 38-46.	1.2	39
179	Ipilimumab in cancer patients. Anti-Cancer Drugs, 2013, 24, 324-326.	1.4	5
180	Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 Patients. Bulletin Du Cancer, 2013, 100, E30-E37.	1.6	6

#	Article	IF	CITATIONS
181	The Issue of Radiation-induced Cardiovascular Toxicity: Preclinical Highlights and Perspectives on Preventive Strategies. Biomedical Journal, 2013, 36, 150.	3.1	5
182	Volumetric modulated arc radiotherapy for limited osteosclerotic myeloma. World Journal of Radiology, 2013, 5, 173.	1.1	2
183	Helical tomotherapy and systemic targeted therapies in solitary plasmacytoma: Pilot study. World Journal of Radiology, 2013, 5, 248.	1.1	4
184	From polychemotherapy regimens to molecular targeting strategies. Biomedical Journal, 2013, 36, 257.	3.1	0
185	Focal 3D conformal high-dose hypofractionated radiotherapy for brain metastases. Melanoma Research, 2012, 22, 406-409.	1.2	2
186	Phase II Trial of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Metastatic Breast Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 18-21.	1.3	12
187	MET targeting: perspectives for the radiation oncologist. Nature Reviews Clinical Oncology, 2012, 9, 548-548.	27.6	0
188	Clear Cell Adenocarcinoma of the Female Genital Tract: Long-Term Outcome and Fertility Aspects After Brachytherapy Aimed at a Conservative Treatment. International Journal of Gynecological Cancer, 2012, 22, 1378-1382.	2.5	9
189	18F-FDG PET/CT Imaging of Sister Mary Joseph's Nodule. Clinical Nuclear Medicine, 2012, 37, 486-488.	1.3	6
190	FOLFIRINOX in Locally Advanced Pancreatic Cancer. Pancreas, 2012, 41, 973-974.	1.1	3
191	Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy. Investigational New Drugs, 2012, 30, 2173-2186.	2.6	2
192	First case of posterior reversible encephalopathy syndrome associated with vinflunine. Investigational New Drugs, 2012, 30, 2032-2034.	2.6	5
193	Primary intracranial extraskeletal myxoid chondrosarcoma. Neurologia I Neurochirurgia Polska, 2012, 46, 76-81.	1.2	10
194	Targeting a cornerstone of radiation resistance: Cancer stem cell. Cancer Letters, 2012, 322, 139-147.	7.2	128
195	Curativeâ€Intended Treatment of Squamous Cell Anal Carcinoma in Elderly Adults. Journal of the American Geriatrics Society, 2012, 60, 1993-1994.	2.6	7
196	Treatment of elderly patients with glioblastoma: From clinical evidence to molecular highlights. Cancer Treatment Reviews, 2012, 38, 988-995.	7.7	24
197	Further developments for improving response and tolerance to irradiation for advanced renal cancer: concurrent (mTOR) inhibitor RAD001 and helical tomotherapy. Investigational New Drugs, 2012, 30, 1241-1243.	2.6	16
198	Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. Investigational New Drugs, 2012, 30, 1116-1120.	2.6	6

#	Article	lF	CITATIONS
199	Place of modern imaging modalities for solitary plasmacytoma: Toward improved primary staging and treatment monitoring. Critical Reviews in Oncology/Hematology, 2012, 82, 150-158.	4.4	17
200	The role of helical tomotherapy in the treatment of bone plasmacytoma. Medical Dosimetry, 2012, 37, 26-30.	0.9	4
201	Correlation of dosimetric parameters obtained with the analytical anisotropic algorithm and toxicity of chest chemoradiation in lung carcinoma. Medical Dosimetry, 2012, 37, 152-156.	0.9	0
202	Case study thoracic radiotherapy in an elderly patient with pacemaker: The issue of pacing leads. Medical Dosimetry, 2012, 37, 192-194.	0.9	8
203	Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. Journal of Neuro-Oncology, 2012, 106, 127-133.	2.9	41
204	Evaluation of circulating tumor cells (CTCs) enumeration and 18F-Choline positron emission tomography/computed tomography (FCH PET/CT) as early efficacy response biomarkers in metastatic castration-resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate Journal of Clinical Oncology, 2012, 30, 63-63.	1.6	2
205	Concurrent use of aromatase inhibitors and hypofractionated radiation therapy. World Journal of Radiology, 2012, 4, 318.	1.1	3
206	In flight auscultation: comparison of electronic and conventional stethoscopes. American Journal of Emergency Medicine, 2011, 29, 932-935.	1.6	17
207	Cardiac toxicity in breast cancer patients: From a fractional point of view to a global assessment. Cancer Treatment Reviews, 2011, 37, 321-330.	7.7	70
208	Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Letters, 2011, 312, 209-218.	7.2	40
209	Whole brain radiotherapy: Prognostic factors and results of a radiation boost delivered through a conventional linear accelerator. Radiotherapy and Oncology, 2011, 99, 214-217.	0.6	22
210	Poorer outcome in Polynesian patients with prostate cancer treated with definitive conformational radiation therapy. Radiotherapy and Oncology, 2011, 101, 502-507.	0.6	1
211	Feasibility of Helical Tomotherapy for Debulking Irradiation Before Stem Cell Transplantation in Malignant Lymphoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1184-1189.	0.8	7
212	Preliminary Results of Whole Brain Radiotherapy With Concurrent Trastuzumab for Treatment of Brain Metastases in Breast Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2011, 81, 631-636.	0.8	96
213	Knowledge and Screening of Testicular Cancer in the French Armed Forces: A Prospective Study. Military Medicine, 2011, 176, 1188-1192.	0.8	6
214	Authors' reply: Whole-brain radiation therapy—concerns about neurotoxicity. Nature Reviews Clinical Oncology, 2011, 8, 506-506.	27.6	0
215	Pentoxifylline to avoid radiation-induced cardiotoxicity: from NF-κB to beyond - a reply to M. Halle and P. Hall and P. Tornvall. Journal of Internal Medicine, 2011, 270, 487-488.	6.0	1
216	Accuracy of Diffusion-Weighted Echo-Planar MR Imaging and ADC Mapping in the evaluation of residual Cervical Carcinoma after radiation therapy. Gynecologic Oncology, 2011, 123, 110-115.	1.4	39

#	Article	IF	CITATIONS
217	Recommendations for a lifestyle which could prevent breast cancer and its relapse: Physical activity and dietetic aspects. Critical Reviews in Oncology/Hematology, 2011, 80, 450-459.	4.4	28
218	Sarcoma of vulva, vagina and ovary. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2011, 25, 797-801.	2.8	23
219	Ultraviolet recall dermatitis reaction with sorafenib. Investigational New Drugs, 2011, 29, 1111-1113.	2.6	7
220	European French-speaking study from the GEMO group on bone metastases management: a special focus on external beam radiotherapy practice survey. Supportive Care in Cancer, 2011, 19, 1565-1572.	2.2	9
221	Interest of diffusionâ€weighted echoâ€planar MR imaging and apparent diffusion coefficient mapping in gynecological malignancies: A review. Journal of Magnetic Resonance Imaging, 2011, 33, 1020-1027.	3.4	74
222	Prostate needle biopsy examination by means of virtual microscopy. Pathology Research and Practice, 2011, 207, 366-369.	2.3	17
223	Current trials of cytotoxic and targeted agents in breast cancer: the caveat of radiotherapy. Annals of Oncology, 2011, 22, 1243-1244.	1.2	2
224	Computed Tomography–Based Simulation for Thoracic Radiation Therapy: Technical Advance or Clinical Evidence?. Journal of Clinical Oncology, 2011, 29, 4335-4336.	1.6	1
225	Applications of new irradiation modalities in patients with lymphoma: Promises and uncertainties. World Journal of Radiology, 2011, 3, 66.	1.1	6
226	External beam radiotherapy in the management of spinal metastases: review of current strategies and perspectives for highly conformal irradiation modalities. Discovery Medicine, 2011, 11, 505-11.	0.5	3
227	The impact of the loco-regional treatment in elderly breast cancer patients: Hypo-fractionated exclusive radiotherapy, single institution long-term results. Breast, 2010, 19, 413-416.	2.2	20
228	Concurrent involved field radiation therapy and Temsirolimus in refractory mantle cell lymphoma (MCL). American Journal of Hematology, 2010, 85, 892-892.	4.1	6
229	Internal Mammary Lymph Node Irradiation Contributes to Heart Dose in Breast Cancer. Medical Dosimetry, 2010, 35, 163-168.	0.9	20
230	Technical aspects and perspectives of the vaginal mold applicator for brachytherapy of gynecologic malignancies. Brachytherapy, 2010, 9, 274-277.	0.5	73
231	Tomorrow's targeted therapies in breast cancer patients: What is the risk for increased radiation-induced cardiac toxicity?. Critical Reviews in Oncology/Hematology, 2010, 76, 186-195.	4.4	28
232	Symptomatic solitary skull bone metastasis as the initial presentation of a testicular germ cell tumor. International Journal of Urology, 2010, 17, 100-100.	1.0	6
233	A Follow-Up Consultation as Cheap as a Postage Stamp. Urologia Internationalis, 2010, 84, 372-372.	1.3	0
234	Pancreatic Metastasis from Prostate Cancer. Case Reports in Medicine, 2010, 2010, 1-2.	0.7	13

#	Article	IF	CITATIONS
235	MRI-based low dose-rate brachytherapy experience in locally advanced cervical cancer patients initially treated by concomitant chemoradiotherapy. Radiotherapy and Oncology, 2010, 96, 161-165.	0.6	57
236	Reappraisal of clinical outcome in adult medulloblastomas with emphasis on patterns of relapse. British Journal of Neurosurgery, 2010, 24, 460-467.	0.8	15
237	Whole-brain radiation therapy in breast cancer patients with brain metastases. Nature Reviews Clinical Oncology, 2010, 7, 632-640.	27.6	33
238	Inhibitors of Angiogenesis. Anesthesiology, 2010, 113, 704-712.	2.5	13
239	Could helical tomotherapy do whole brain radiotherapy and radiosurgery?. World Journal of Radiology, 2010, 2, 148.	1.1	8
240	Impact on Cardiac Toxicity With Trastuzumab and Radiotherapy: The Question Is Still Ongoing. Journal of Clinical Oncology, 2009, 27, e239-e239.	1.6	15
241	Potential of Helical Tomotherapy for Sparing Critical Organs in a Patient with AIDS Who Was Treated for Hodgkin Lymphoma. Clinical Infectious Diseases, 2009, 48, 687-689.	5.8	9
242	Solitary plasmocytoma: improvement in critical organs sparing by means of helical tomotherapy. European Journal of Haematology, 2009, 83, 66-71.	2.2	14
243	Improve the management of patients with skull bone metastases by means of helical tomotherapy. Supportive Care in Cancer, 2009, 17, 613-615.	2.2	3
244	Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. Journal of Neuro-Oncology, 2009, 93, 379-384.	2.9	33
245	Clinical and Therapeutic Aspects in Elderly Patients with Merkel Cell Carcinoma: Special Focus on Radiotherapy. Journal of the American Geriatrics Society, 2009, 57, 1946-1947.	2.6	5
246	Concomitant chemo-radiotherapy in clinical trials: To promote step by step rational development. Critical Reviews in Oncology/Hematology, 2009, 70, 206-215.	4.4	6
247	Physics Contributions and Clinical Outcome With 3D-MRI–Based Pulsed-Dose-Rate Intracavitary Brachytherapy in Cervical Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2009, 74, 133-139.	0.8	137
248	Progressive inflammatory breast cancer in patient receiving chemotherapy: The importance of radiotherapy as a part of locoregional treatment. Radiotherapy and Oncology, 2009, 90, 160-161.	0.6	9
249	Severe acute radiation-related skin toxicity in a breast cancer patient with Behçet's disease. Radiotherapy and Oncology, 2009, 91, 139.	0.6	5
250	DVH parameters and outcome for patients with early-stage cervical cancer treated with preoperative MRI-based low dose rate brachytherapy followed by surgery. Radiotherapy and Oncology, 2009, 93, 316-321.	0.6	58
251	Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale?. Lancet Oncology, The, 2009, 10, 53-60.	10.7	51
252	Concurrent hormone and radiation therapy in patients with breast cancer: how does chemotherapy affect treatment? – Authors' reply. Lancet Oncology, The, 2009, 10, 445-446.	10.7	0

#	Article	IF	CITATIONS
253	Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients. Radiotherapy and Oncology, 2009, 90, 116-121.	0.6	16
254	Preliminary experience of helical tomotherapy for locally advanced pancreatic cancer. World Journal of Gastroenterology, 2009, 15, 4444.	3.3	7
255	Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents. Cancer and Metastasis Reviews, 2008, 27, 737-750.	5.9	11
256	The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials. European Journal of Cancer, 2008, 44, 2133-2143.	2.8	24
257	Nutritional support during oncologic treatment of patients with gastrointestinal cancer: Who could benefit?. Cancer Treatment Reviews, 2008, 34, 568-575.	7.7	106
258	New trends in the evaluation and treatment of cervix cancer: The role of FDG–PET. Cancer Treatment Reviews, 2008, 34, 671-681.	7.7	68
259	Reapprasial of the role of endocrine therapy in meningioma management. Endocrine-Related Cancer, 2008, 15, 931-941.	3.1	12
260	"Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects― Nature Clinical Practice Oncology, 2008, 5, E1-E1.	4.3	6
261	Longâ€ŧerm urological complications after conservative local treatment (surgery and brachytherapy) in children with bladder–prostate rhabdomyosarcoma: A singleâ€ŧeam experience. Pediatric Blood and Cancer, 0, , e29532.	1.5	5